In addition, an in vitro MLR with splenocytes, harvested from BM recipients after rejection of the first skin graft, revealed no significant difference regarding proliferation of both CD4+ and CD8+ T cells whether recipients were treated with anti-IL-6 or not, which is consistent with the in vivo results of skin graft rejection (Figure 4I). The gene discussed is CD4; the disease is medical procedure.